New Drug Offers 24-Hour Blood Pressure Control, Promises Hope

A groundbreaking trial has unveiled a new drug, baxdrostat, which provides continuous protection against high blood pressure, even during critical periods when the risk of heart attacks and strokes peaks. The findings, published on November 9, 2025, highlight the drug’s potential to significantly enhance treatment options for those with treatment-resistant hypertension.

High blood pressure is often linked to the hormone aldosterone, produced by the adrenal glands, which regulates sodium and potassium levels in the body. In some individuals, excessive aldosterone secretion leads to increased blood pressure as the body retains salt and water. While existing medications can block aldosterone’s effects, baxdrostat represents a novel approach by directly inhibiting its production.

The global study, known as the Bax24 trial, included 218 participants from 79 locations worldwide, all suffering from treatment-resistant hypertension. This condition persists despite the use of at least three different antihypertensive medications. The research was led by Professor Bryan Williams, a cardiovascular science expert at University College London.

Professor Williams stated, “The trial results are quite remarkable both in terms of the magnitude of blood pressure reduction and the fact that it was sustained across the entire 24-hour period.” He emphasized that the drug’s efficacy suggests a significant role for aldosterone in driving hypertension, particularly in patients who are challenging to treat with current therapies.

Participants in the trial received either baxdrostat or a placebo daily, in addition to their regular medications. Blood pressure was monitored using a 24-hour ambulatory blood pressure monitoring (ABPM) device, which offers a more accurate assessment than traditional clinical measurements. After a 12-week period, those taking baxdrostat experienced a notable reduction in blood pressure throughout the day and night, including during early morning hours, when the risk of cardiovascular events is highest.

The results were presented at a late-breaking session during the American Association of Cardiovascular Scientists’ meeting in New Orleans. In a previous phase of research involving 800 patients, baxdrostat was shown to decrease blood pressure by approximately 9 to 10 mmHg more than the placebo, with around 40% of participants achieving healthy blood pressure levels compared to less than 20% in the placebo group. Importantly, no unexpected safety issues arose during the trials.

If approved, baxdrostat could greatly benefit the estimated 14 million individuals in the UK living with high blood pressure, many of whom have uncontrolled or treatment-resistant cases. The British Heart Foundation highlights that numerous individuals may remain unaware of their high blood pressure, which can lead to severe complications such as heart attacks, strokes, and kidney disease.

Symptoms of high blood pressure can include headaches, blurred vision, and chest pain. Risk factors include age, family history, ethnicity, dietary habits, obesity, smoking, alcohol consumption, and stress. Individuals concerned about their blood pressure can seek testing at pharmacies or local clinics, with many offering free checks for those aged 40 and older.

AstraZeneca, the manufacturer of baxdrostat, is preparing to apply for regulatory approval, with hopes that the drug could become available on the National Health Service (NHS) as early as next year. This development marks a significant step forward in the fight against hypertension and offers hope for millions struggling with this chronic condition.